Arteriosclerosis, thrombosis, and vascular biology.
Publisher:
American Heart Association,. Baltimore, Md. : Lippincott Williams & Wilkins (1998)
Frequency: Monthly
Country: United States
Language: English
Author(s):
American Heart Association.
Start Year:1995 -
Identifiers
| ISSN: | 1079-5642 (Print) 1524-4636 (Electronic) 1079-5642 (Linking) |
| NLM ID: | 9505803 |
| (DNLM): | SR0082891(s) |
| (OCoLC): | 31441121 |
| Coden: | ATVBFA |
| LCCN: | sn 94003077 |
| Classification: | W1 AR9515E |
Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Although estrogen replacement therapy is associated with reduced risk of coronary heart disease and reduced extent of coronary artery atherosclerosis, the effects of combined (estrogen plus progestin) hormone-replacement therapy are uncertain. Some observational data indicate that users of combined hormone replacement consisting of continuously administered oral conjugated equine estrogens (CEE) and oral sequentially administered (7 to 14 days per month) medroxyprogesterone acetate (MPA) experience a reduction in risk similar to that of users of CEE alone. However, the effects of combined, con...